Establishment Labs to Host Investor Event for Mia Femtech on October 5, 2022

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will host an investor event on October 5, 2022, at 4:30 p.m. ET, to discuss its innovative product, Mia Femtech®. This minimally invasive procedure aims to enhance breast aesthetics, allowing for a breast size increase of 1 to 2 cups in just 15 minutes, without general anesthesia. The company is pursuing regulatory approvals for Mia in Europe and anticipates commercialization in select markets in the first half of 2023.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it will host an investor event on October 5, 2022 to discuss Mia Femtech^® (“Mia”). A webcast of the event will begin at 4:30 p.m. Eastern Time.

Mia Femtech^® is Establishment Labs’ minimally invasive breast aesthetics experience. The patented technologies used with Mia can increase breast size by 1 to 2 cups in a 15-minute procedure without the need for general anesthesia. The Company will provide an overview of Mia as well as updates on the progress to date in development and commercialization.

Event Details
Date: Wednesday, October 5, 2022
Time: 4:30 – 5:30 p.m. ET
To participate, please click: registration link

After the conclusion of the program, there will be a question and answer session for investors and analysts. A recording of the event will be archived on the Company’s website.

The Company is currently pursuing regulatory approvals for Mia Femtech^® in Europe and other geographies and expects to begin commercialization in select markets in the first half of 2023. Mia Femtech^® is currently not approved for commercial distribution in the United States. Motiva Implants^® are undergoing clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants^® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, over 2.0 million Motiva Implants^® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora^® tissue expander and Mia Femtech^®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant^® and began a clinical trial to support regulatory approval in the United States. Motiva Implants^® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, our liquidity and anticipated cash plans; anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this press release, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our cash requirements and ability to generate positive cash flow from operations; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; the effect on our business of the current Russia-Ukraine conflict; the impact of foreign currency exchange rates; the impact on our business of an economic downturn or deterioration of general macroeconomic conditions, including slower growth or recession, inflation or decreases in consumer spending power or confidence; other economic and competitive factors; and the other risks and uncertainties discussed in Item 1A, Risk Factors, in the company’s annual report on Form 10-K filed on March 1, 2022, as such risks and uncertainties will be updated in the company's quarterly report on Form 10-Q for the three months ended June 30, 2022, which is expected to be filed with the SEC on August 9, 2022. These and other factors that could cause or contribute to actual results differing materially from our expectations may also be amended, updated or superseded from time to time in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920006158/en/

Investor/Media Contact:

Raj Denhoy

415 828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

What is the purpose of the investor event hosted by Establishment Labs on October 5, 2022?

The investor event aims to discuss the company's innovative product, Mia Femtech®, which is a minimally invasive breast aesthetics procedure.

What time does the Establishment Labs investor event start on October 5, 2022?

The investor event will start at 4:30 p.m. Eastern Time on October 5, 2022.

What are the expected benefits of Mia Femtech® according to Establishment Labs?

Mia Femtech® can increase breast size by 1 to 2 cups in a 15-minute procedure without the need for general anesthesia.

When does Establishment Labs expect to begin commercialization of Mia Femtech®?

Establishment Labs expects to begin commercialization of Mia Femtech® in select markets in the first half of 2023.

Is Mia Femtech® currently approved for distribution in the United States?

No, Mia Femtech® is not approved for commercial distribution in the United States.